Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $137.78 USD
Change Today +0.66 / 0.48%
Volume 133.5K
BDX On Other Exchanges
As of 10:44 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/15 - $154.98
52 Week Low
10/16/14 - $120.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BECTON DICKINSON AND CO (BDX)

becton dickinson and co (BDX) Related Businessweek News

View More BusinessWeek News

becton dickinson and co (BDX) Details

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company’s BD Medical segment produces medical devices, such as needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for use in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices. Its BD Life Sciences segment provides products for the collection and transportation of diagnostics specimens; and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections, and cancers. This segment’s products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood and tuberculosis culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. It also offers research and clinical tools, such as fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. In addition, the company develops technologies that address biological analysis protocols, including library preparation of next generation sequencing and genotyping applications. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. It has a collaboration with Seegene, Inc. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

30,619 Employees
Last Reported Date: 11/26/14
Founded in 1897

becton dickinson and co (BDX) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $985.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $690.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $721.0K
Executive Vice President and President of Glo...
Total Annual Compensation: $605.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $900.8K
Compensation as of Fiscal Year 2014.

becton dickinson and co (BDX) Key Developments

BD Launches the BD FACSseq Cell Sorter with BD Precise Assays for High Precision Single Cell Genomics

BD Life Sciences launched its first dedicated product specifically for single cell genomics applications with BD FACSseqTM, a high-throughput cell sorter designed for single cell genomic studies, combined with BDTM Precise Assays for single cell gene expression analysis. A poster demonstrating the performance of the BD FACSseq cell sorter and BD Precise Assays for targeted gene expression will be presented at the American Society of Human Genetics (ASHG) 2015 Annual Meeting. The BD FACSseq cell sorter and BD Precise Assays are currently for research use only. Understanding the genomic differences of individual cell types provides unique insights into disease characteristics that have the potential to identify new approaches for developing targeted therapeutics. The BD FACSseq cell sorter combined with BD Precise Assays offers a high-throughput research method for single cell gene expression analysis to enable thousands of cells to be analyzed accurately, quickly, easily and affordably. BD Precise Assays, a product line developed at Cellular Research Inc. which was recently acquired by BD, allows for a high throughput single cell genetic analysis based on their proprietary Molecular Indexing technology to enable gene expression profiles from single cells. This technology, combined with BD's cell sorting capabilities, provides for a simple and integrated workflow for single cell analysis.

BD MAX Enteric Parasite Panel Receives FDA Clearance for Detection of Common and Pathogenic Intestinal Parasites

BD Life Sciences announced the availability of the U.S. Food and Drug Administration (FDA) cleared BD MAX Enteric Parasite Panel for use on the BD MAX System. The BD MAX Enteric Parasite Panel is the latest panel in the BD MAX Enteric suite of assays that aid in the diagnosis of infectious gastroenteritis. This panel joins the BD MAX Enteric Bacterial Panel detecting the pathogens that are responsible for up to 95% of the bacteria causing gastroenteritis.i With the availability of the BD MAX Enteric Parasite Panel, the majority of pathogens causing this disease can be detected with a fully automated, rapid and accurate platform. The BD MAX Enteric Parasite Panel is a qualitative IVD test detecting DNA from Giardia lamblia, Cryptosporidium (C. hominis and C. parvum) and Entamoeba histolytica in both unpreserved and 10% formalin-fixed stool specimens. In the laboratory, the BD MAX System automates sample preparation, extraction, amplification and detection on a single system, saving time and improving lab efficiency. Molecular testing on the BD MAX System is simplified and standardized, to minimize variability in results. The BD MAX menu includes syndromic panels for Healthcare Associated Infections, Reproductive & Sexually Transmitted Infections and Enteric Pathogens, enabling lab professionals in their efforts to deliver diagnostic results that improve lab operations.

Seegene Inc. and BD Life Sciences Enter into Worldwide Collaboration Agreement

Seegene Inc. and BD Life Sciences have entered into a worldwide collaboration agreement to co-develop multiplex real-time PCR reagents for the BD MAX System. Under the terms of the agreement, Seegene will develop and manufacture multiplex tests based on novel DPO, TOCE, and MuDT technologies designed exclusively for BD's molecular diagnostics platform. BD, in turn, will have worldwide commercialization rights to these tests.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $137.78 USD +0.66

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,582 JPY +58.00
Avago Technologies Ltd $117.23 USD +0.54
Boston Scientific Corp $16.75 USD -0.04
Mylan NV $42.57 USD -0.10
Stryker Corp $98.33 USD +0.98
View Industry Companies

Industry Analysis


Industry Average

Valuation BDX Industry Range
Price/Earnings 33.4x
Price/Sales 3.0x
Price/Book 3.9x
Price/Cash Flow 34.7x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at